Allogene Therapeutics (ALLO) Financials

$1.46 +0.03 (+2.10%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$1.47 +0.01 (+0.68%)

As of 04/15/2025 07:25 PM Eastern

Annual Income Statements for Allogene Therapeutics

This table shows Allogene Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-340	-327	-258
Consolidated Net Income / (Loss)	-340	-327	-258
Net Income / (Loss) Continuing Operations	-340	-327	-258
Total Pre-Tax Income	-340	-327	-257
Total Operating Income	-336	-328	-273
Total Gross Profit	0.16	0.10	0.02
Total Revenue	0.16	0.10	0.02
Operating Revenue	0.16	0.10	0.02
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	336	328	273
Selling, General & Admin Expense	79	72	65
Research & Development Expense	256	243	192
Impairment Charge	0.00	13	16
Total Other Income / (Expense), net	-4.88	0.47	16
Interest Expense	-	0.00	0.18
Interest & Investment Income	4.57	18	20
Other Income / (Expense), net	-9.44	-18	-3.92
Income Tax Expense	-	0.00	0.44
Basic Earnings per Share	($2.38)	($2.09)	($1.32)
Weighted Average Basic Shares Outstanding	143.15M	156.93M	194.81M
Diluted Earnings per Share	($2.38)	($2.09)	($1.32)
Weighted Average Diluted Shares Outstanding	143.15M	156.93M	194.81M
Weighted Average Basic & Diluted Shares Outstanding	144.50M	169.09M	217.26M
Cash Dividends to Common per Share	$0.00	$0.00	$0.00

This table shows Allogene Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-83	-103	-100	-79	-62	-86	-65	-66	-66	-60
Consolidated Net Income / (Loss)	-83	-103	-100	-79	-62	-86	-65	-66	-66	-60
Net Income / (Loss) Continuing Operations	-83	-103	-100	-79	-62	-86	-65	-66	-66	-60
Total Pre-Tax Income	-83	-103	-100	-79	-62	-86	-65	-66	-66	-59
Total Operating Income	-82	-96	-99	-81	-63	-85	-70	-71	-72	-60
Total Operating Expenses	83	96	99	81	63	85	70	71	72	60
Selling, General & Admin Expense	19	21	19	19	17	17	17	16	16	16
Research & Development Expense	64	75	80	62	46	55	52	50	45	45
Total Other Income / (Expense), net	-0.66	-6.17	-0.88	1.31	0.71	-0.67	4.50	5.07	5.48	0.99
Other Income / (Expense), net	-1.66	-9.42	-0.88	-2.47	-5.50	-8.99	4.50	0.09	-1.12	-7.39
Basic Earnings per Share	($0.58)	($0.72)	($0.69)	($0.54)	($0.37)	($0.49)	($0.38)	($0.35)	($0.32)	($0.27)
Weighted Average Basic Shares Outstanding	143.66M	143.15M	144.56M	146.80M	167.65M	156.93M	169.13M	190.03M	209.19M	194.81M
Diluted Earnings per Share	($0.58)	($0.72)	($0.69)	($0.54)	($0.37)	($0.49)	($0.38)	($0.35)	($0.32)	($0.27)
Weighted Average Diluted Shares Outstanding	143.66M	143.15M	144.56M	146.80M	167.65M	156.93M	169.13M	190.03M	209.19M	194.81M
Weighted Average Basic & Diluted Shares Outstanding	144.21M	144.50M	145.84M	167.63M	168.28M	169.09M	170.85M	209.11M	209.67M	217.26M

This table details how cash moves in and out of Allogene Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-111	21	-7.94
Net Cash From Operating Activities	-221	-238	-200
Net Cash From Continuing Operating Activities	-221	-238	-200
Net Income / (Loss) Continuing Operations	-340	-327	-258
Consolidated Net Income / (Loss)	-340	-327	-258
Depreciation Expense	14	14	14
Non-Cash Adjustments To Reconcile Net Income	102	91	62
Changes in Operating Assets and Liabilities, net	3.90	-15	-18
Net Cash From Investing Activities	106	163	76
Net Cash From Continuing Investing Activities	106	163	76
Purchase of Property, Plant & Equipment	-5.19	-1.52	-0.69
Purchase of Investments	-248	-439	-361
Sale and/or Maturity of Investments	359	603	438
Net Cash From Financing Activities	2.95	96	117
Net Cash From Continuing Financing Activities	2.95	96	117
Issuance of Common Equity	2.95	96	114
Other Financing Activities, net	-	0.00	2.28

This table details how cash moves in and out of Allogene Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-22	-12	48	45	-86	14	-32	120	-119	24
Net Cash From Operating Activities	-48	-62	-67	-62	-56	-54	-56	-64	-44	-37
Net Cash From Continuing Operating Activities	-48	-62	-67	-62	-56	-54	-56	-64	-44	-37
Net Income / (Loss) Continuing Operations	-83	-103	-100	-79	-62	-86	-65	-66	-66	-60
Consolidated Net Income / (Loss)	-83	-103	-100	-79	-62	-86	-65	-66	-66	-60
Depreciation Expense	3.86	3.07	3.51	3.64	3.57	3.48	3.56	3.64	3.21	3.23
Non-Cash Adjustments To Reconcile Net Income	24	26	22	18	22	28	9.99	16	23	13
Changes in Operating Assets and Liabilities, net	7.79	11	7.42	-4.36	-19	0.93	-4.44	-17	-4.35	7.05
Net Cash From Investing Activities	25	50	113	17	-34	67	22	75	-76	55
Net Cash From Continuing Investing Activities	25	50	113	17	-34	67	22	75	-76	55
Purchase of Property, Plant & Equipment	-0.22	-1.69	-1.04	-0.29	-0.01	-0.18	-0.01	-	-0.43	-0.26
Purchase of Investments	-49	-48	-35	-135	-199	-69	-81	-43	-191	-47
Sale and/or Maturity of Investments	75	99	149	153	165	136	103	117	115	102
Net Cash From Financing Activities	1.07	0.05	1.73	90	4.29	0.16	1.65	109	0.68	5.74
Net Cash From Continuing Financing Activities	1.07	0.05	1.73	90	4.29	0.16	1.65	109	0.68	5.74
Issuance of Common Equity	1.07	0.05	1.73	90	4.29	0.16	1.65	106	0.68	5.74

This table presents Allogene Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	822	643	549
Total Current Assets	529	459	303
Cash & Equivalents	62	83	75
Short-Term Investments	455	366	217
Prepaid Expenses	12	10	11
Plant, Property, & Equipment, net	113	99	86
Total Noncurrent Assets	180	84	159
Long-Term Investments	76	3.65	81
Other Noncurrent Operating Assets	103	81	79
Total Liabilities & Shareholders' Equity	822	643	549
Total Liabilities	155	131	127
Total Current Liabilities	54	37	36
Accounts Payable	14	5.90	5.39
Accrued Expenses	40	31	30
Total Noncurrent Liabilities	101	94	91
Other Noncurrent Operating Liabilities	101	94	91
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	667	512	422
Total Preferred & Common Equity	667	512	422
Preferred Stock	0.00	0.00	0.00
Total Common Equity	667	512	422
Common Stock	1,912	2,075	2,242
Retained Earnings	-1,235	-1,562	-1,820
Accumulated Other Comprehensive Income / (Loss)	-9.93	-0.96	-0.09

This table presents Allogene Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	888	747	771	712	586	647	589
Total Current Assets	569	481	502	473	395	457	304
Cash & Equivalents	74	110	155	69	51	171	51
Short-Term Investments	478	361	337	396	334	274	240
Prepaid Expenses	17	10	10	7.95	11	12	13
Plant, Property, & Equipment, net	114	110	106	103	96	92	89
Total Noncurrent Assets	204	156	162	136	95	98	196
Long-Term Investments	99	54	62	38	15	1.13	112
Other Noncurrent Operating Assets	105	102	100	99	80	97	84
Total Liabilities & Shareholders' Equity	888	747	771	712	586	647	589
Total Liabilities	148	155	148	129	125	132	125
Total Current Liabilities	49	60	55	38	31	37	33
Accounts Payable	11	15	10	6.21	5.78	13	5.51
Accrued Expenses	37	45	44	31	25	24	27
Total Noncurrent Liabilities	99	95	93	92	94	95	93
Other Noncurrent Operating Liabilities	99	95	93	92	94	95	93
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	740	592	623	583	461	515	464
Total Preferred & Common Equity	740	592	623	583	461	515	464
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	740	592	623	583	461	515	464
Common Stock	1,894	1,933	2,039	2,060	2,090	2,209	2,223
Retained Earnings	-1,141	-1,335	-1,413	-1,474	-1,627	-1,694	-1,760
Accumulated Other Comprehensive Income / (Loss)	-13	-5.93	-3.85	-2.41	-0.93	-0.78	0.16

This table displays calculated financial ratios and metrics derived from Allogene Therapeutics' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	-99.86%	-39.10%	-76.84%
EBITDA Growth	-90.80%	-0.21%	20.49%
EBIT Growth	-87.73%	-0.17%	19.81%
NOPAT Growth	-86.21%	2.32%	16.64%
Net Income Growth	-86.99%	3.86%	21.29%
EPS Growth	-77.61%	12.18%	36.84%
Operating Cash Flow Growth	-19.32%	-7.81%	15.75%
Free Cash Flow Firm Growth	-32.49%	2.80%	16.57%
Invested Capital Growth	-14.53%	-18.06%	-18.13%
Revenue Q/Q Growth	-99.79%	-43.79%	-48.84%
EBITDA Q/Q Growth	-49.03%	3.55%	8.98%
EBIT Q/Q Growth	-45.34%	3.30%	8.65%
NOPAT Q/Q Growth	-41.36%	3.35%	8.27%
Net Income Q/Q Growth	-43.21%	4.90%	9.12%
EPS Q/Q Growth	-44.24%	9.91%	14.29%
Operating Cash Flow Q/Q Growth	-8.17%	3.41%	7.83%
Free Cash Flow Firm Q/Q Growth	-35.30%	5.52%	4.45%
Invested Capital Q/Q Growth	-17.48%	-25.19%	-18.77%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-211,977.56%	-348,813.68%	-1,197,636.36%
Operating Margin	-215,087.18%	-344,986.32%	-1,241,813.64%
EBIT Margin	-221,141.03%	-363,760.00%	-1,259,631.82%
Profit (Net Income) Margin	-218,214.10%	-344,489.47%	-1,170,863.64%
Tax Burden Percent	100.00%	100.00%	100.17%
Interest Burden Percent	98.68%	94.70%	92.79%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-296.16%	-345.03%	-351.15%
ROIC Less NNEP Spread (ROIC-NNEP)	-281.43%	-326.32%	-335.08%
Return on Net Nonoperating Assets (RNNOA)	253.40%	289.52%	296.02%
Return on Equity (ROE)	-42.76%	-55.51%	-55.13%
Cash Return on Invested Capital (CROIC)	-280.49%	-325.17%	-331.21%
Operating Return on Assets (OROA)	-36.85%	-47.20%	-46.51%
Return on Assets (ROA)	-36.36%	-44.70%	-43.24%
Return on Common Equity (ROCE)	-42.76%	-55.51%	-55.13%
Return on Equity Simple (ROE_SIMPLE)	-51.05%	-63.89%	-61.01%
Net Operating Profit after Tax (NOPAT)	-235	-229	-191
NOPAT Margin	-150,561.03%	-241,490.42%	-869,269.55%
Net Nonoperating Expense Percent (NNEP)	-14.73%	-18.71%	-16.08%
Return On Investment Capital (ROIC_SIMPLE)	-	-44.79%	-45.30%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	50,836.54%	75,445.26%	296,386.36%
R&D to Revenue	164,350.64%	255,698.95%	874,086.36%
Operating Expenses to Revenue	215,187.18%	345,086.32%	1,241,913.64%
Earnings before Interest and Taxes (EBIT)	-345	-346	-277
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-331	-331	-263
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.36	1.05	1.06
Price to Tangible Book Value (P/TBV)	1.36	1.05	1.06
Price to Revenue (P/Rev)	5,814.63	5,685.98	20,300.07
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.29	1.47	1.50
Enterprise Value to Revenue (EV/Rev)	2,008.29	924.49	3,338.75
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.90	-0.89	-0.88
Leverage Ratio	1.18	1.24	1.28
Compound Leverage Factor	1.16	1.18	1.18
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	0.72	-1.91	-3.61
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.84	12.38	8.54
Quick Ratio	9.63	12.10	8.23
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-222	-216	-180
Operating Cash Flow to CapEx	-4,248.10%	-15,681.60%	-28,861.67%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-996.57
Operating Cash Flow to Interest Expense	0.00	0.00	-1,106.63
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-1,110.46
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	73	60	49
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-12	-13	-11
Enterprise Value (EV)	313	88	73
Market Capitalization	907	540	447
Book Value per Share	$4.62	$3.04	$2.01
Tangible Book Value per Share	$4.62	$3.04	$2.01
Total Capital	667	512	422
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-594	-452	-373
Capital Expenditures (CapEx)	5.19	1.52	0.69
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-42	-27	-25
Debt-free Net Working Capital (DFNWC)	475	422	268
Net Working Capital (NWC)	475	422	268
Net Nonoperating Expense (NNE)	106	98	66
Net Nonoperating Obligations (NNO)	-594	-452	-373
Total Depreciation and Amortization (D&A)	14	14	14
Debt-free, Cash-free Net Working Capital to Revenue	-27,066.67%	-28,064.21%	-111,877.27%
Debt-free Net Working Capital to Revenue	304,548.72%	444,248.42%	1,217,559.09%
Net Working Capital to Revenue	304,548.72%	444,248.42%	1,217,559.09%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	($2.09)	($1.32)
Adjusted Weighted Average Basic Shares Outstanding	0.00	156.93M	194.81M
Adjusted Diluted Earnings per Share	$0.00	($2.09)	($1.32)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	156.93M	194.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	169.09M	217.26M
Normalized Net Operating Profit after Tax (NOPAT)	-235	-220	-180
Normalized NOPAT Margin	-150,561.03%	-231,730.95%	-819,260.91%
Pre Tax Income Margin	-218,214.10%	-344,489.47%	-1,168,850.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	-1,531.04
NOPAT to Interest Expense	0.00	0.00	-1,056.57
EBIT Less CapEx to Interest Expense	0.00	0.00	-1,534.88
NOPAT Less CapEx to Interest Expense	0.00	0.00	-1,060.41
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Allogene Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-99.87%	-50.82%	0.00%	0.00%	-77.89%	-26.67%	-100.00%	-100.00%	0.00%
EBITDA Growth	-6.57%	-1,827.90%	-26.66%	-11.12%	19.14%	11.85%	36.30%	14.70%	-7.35%	28.67%
EBIT Growth	-8.34%	-6,298.95%	-25.19%	-10.53%	18.61%	11.12%	34.98%	14.05%	-6.43%	27.87%
NOPAT Growth	-6.20%	-4,053.32%	-23.88%	-5.15%	23.63%	11.77%	29.86%	11.31%	-13.93%	28.93%
Net Income Growth	-6.35%	-119,436.05%	-25.19%	-5.94%	25.09%	16.42%	34.98%	16.25%	-6.43%	30.12%
EPS Growth	-1.75%	-7,300.00%	-23.21%	-3.85%	36.21%	31.94%	44.93%	35.19%	13.51%	44.90%
Operating Cash Flow Growth	2.50%	-36.67%	2.34%	-45.44%	-16.53%	13.51%	16.12%	-2.80%	20.56%	31.67%
Free Cash Flow Firm Growth	29.56%	-37.57%	63.14%	60.14%	36.46%	15.83%	-50.01%	-105.77%	14.16%	32.11%
Invested Capital Growth	-1.93%	-14.53%	-37.78%	-31.64%	-9.61%	-18.06%	-8.55%	1.21%	-24.60%	-18.13%
Revenue Q/Q Growth	0.00%	0.00%	-68.42%	-26.67%	0.00%	-4.55%	-48.84%	-100.00%	0.00%	0.00%
EBITDA Q/Q Growth	-12.41%	-28.05%	6.18%	17.72%	18.20%	-39.59%	32.92%	-10.18%	-2.94%	7.24%
EBIT Q/Q Growth	-12.05%	-25.82%	5.58%	16.96%	17.49%	-37.39%	31.63%	-9.76%	-2.18%	6.89%
NOPAT Q/Q Growth	-7.70%	-16.94%	-2.73%	18.72%	21.78%	-35.10%	18.36%	-2.77%	-0.48%	15.72%
Net Income Q/Q Growth	-11.18%	-23.43%	2.59%	20.74%	21.39%	-37.71%	25.07%	-2.09%	0.10%	9.58%
EPS Q/Q Growth	-11.54%	-24.14%	4.17%	21.74%	31.48%	-32.43%	22.45%	7.89%	8.57%	15.63%
Operating Cash Flow Q/Q Growth	-12.05%	-30.30%	-7.32%	7.18%	10.23%	3.28%	-4.08%	-13.76%	30.62%	16.81%
Free Cash Flow Firm Q/Q Growth	9.65%	1.60%	48.08%	13.65%	-44.04%	-30.33%	7.49%	-18.45%	39.91%	-3.08%
Invested Capital Q/Q Growth	-11.53%	-17.48%	-8.16%	1.97%	16.97%	-25.19%	2.50%	12.85%	-12.87%	-18.77%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	-108,221.05%	-321,536.67%	-360,759.09%	-295,090.91%	-431,547.62%	-279,295.45%	0.00%	0.00%	0.00%
Operating Margin	0.00%	-101,537.89%	-330,306.67%	-366,090.91%	-286,345.45%	-405,280.95%	-315,927.27%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	-111,450.53%	-333,226.67%	-377,318.18%	-311,327.27%	-448,104.76%	-295,454.55%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	-108,030.53%	-333,226.67%	-360,145.45%	-283,122.73%	-408,466.67%	-295,454.55%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.74%
Interest Burden Percent	98.81%	96.93%	100.00%	95.45%	90.94%	91.15%	100.00%	93.01%	90.94%	87.66%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-139.81%	-330.29%	-446.94%	-401.74%	-405.33%	-299.43%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-134.91%	-325.48%	-443.30%	-398.59%	-400.32%	-295.89%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	121.47%	286.13%	390.86%	347.78%	355.17%	259.80%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-18.34%	-44.16%	-56.08%	-53.96%	-50.16%	-39.62%	0.00%	0.00%	0.00%
Cash Return on Invested Capital (CROIC)	-183.80%	-280.49%	-237.12%	-260.22%	-271.40%	-325.17%	-315.87%	-295.02%	-268.86%	-331.21%
Operating Return on Assets (OROA)	0.00%	-18.57%	-48.67%	-64.55%	-65.77%	-58.14%	-38.56%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	-18.00%	-48.67%	-61.61%	-59.81%	-53.00%	-38.56%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	0.00%	-18.34%	-44.16%	-56.08%	-53.96%	-50.16%	-39.62%	0.00%	0.00%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-32.12%	0.00%	-60.87%	-58.59%	-59.01%	0.00%	-63.35%	-54.25%	-61.12%	0.00%
Net Operating Profit after Tax (NOPAT)	-58	-68	-69	-56	-44	-60	-49	-50	-50	-42
NOPAT Margin	0.00%	-71,076.53%	-231,214.67%	-256,263.64%	-200,441.82%	-283,696.67%	-221,149.09%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-3.32%	-4.90%	-4.81%	-3.64%	-3.15%	-5.01%	-3.53%	-3.27%	-3.54%	-4.26%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-11.63%	-	-	-	-10.03%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	22,107.37%	62,946.67%	84,200.00%	77,459.09%	82,019.05%	78,486.36%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	79,388.42%	267,460.00%	281,990.91%	208,986.36%	260,290.48%	237,540.91%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	101,495.79%	330,406.67%	366,190.91%	286,445.45%	405,380.95%	316,027.27%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-84	-106	-100	-83	-68	-94	-65	-71	-73	-68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-80	-103	-96	-79	-65	-91	-61	-68	-70	-65
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.10	1.36	1.21	1.16	0.91	1.05	1.64	0.77	1.26	1.06
Price to Tangible Book Value (P/TBV)	2.10	1.36	1.21	1.16	0.91	1.05	1.64	0.77	1.26	1.06
Price to Revenue (P/Rev)	20.49	5,814.63	5,710.54	4,930.84	3,144.23	5,685.98	8,687.83	6,124.44	13,616.56	20,300.07
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	10.18	4.29	2.81	2.49	0.35	1.47	5.80	0.00	3.02	1.50
Enterprise Value to Revenue (EV/Rev)	11.90	2,008.29	1,509.45	1,159.01	167.67	924.49	4,090.35	0.00	4,235.52	3,338.75
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.90	-0.90	-0.88	-0.88	-0.87	-0.89	-0.88	-0.88	-0.87	-0.88
Leverage Ratio	1.15	1.18	1.18	1.21	1.21	1.24	1.27	1.25	1.24	1.28
Compound Leverage Factor	1.14	1.14	1.18	1.15	1.10	1.13	1.27	1.16	1.13	1.12
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	4.99	1.68	0.50	0.71	-0.01	-0.62	0.12	-1.44	-1.23	-2.35
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.64	9.84	8.08	9.18	12.58	12.38	12.80	12.25	9.35	8.54
Quick Ratio	11.30	9.63	7.91	8.99	12.37	12.10	12.46	11.92	8.95	8.23
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-56	-55	-29	-25	-36	-46	-43	-51	-31	-31
Operating Cash Flow to CapEx	-21,369.96%	-3,669.98%	-6,438.55%	-21,478.13%	-462,750.00%	-29,672.38%	-698,737.50%	0.00%	-10,283.22%	-14,279.38%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-305.43	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-441.15	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-445.44	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	89	73	67	68	80	60	61	69	60	49
Invested Capital Turnover	0.85	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-1.75	-12	-41	-32	-8.52	-13	-5.74	0.83	-20	-11
Enterprise Value (EV)	902	313	189	170	28	88	356	-48	182	73
Market Capitalization	1,553	907	714	725	531	540	756	398	586	447
Book Value per Share	$5.15	$4.62	$4.10	$4.27	$3.48	$3.04	$2.73	$3.01	$2.22	$2.01
Tangible Book Value per Share	$5.15	$4.62	$4.10	$4.27	$3.48	$3.04	$2.73	$3.01	$2.22	$2.01
Total Capital	740	667	592	623	583	512	461	515	464	422
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-651	-594	-525	-554	-503	-452	-400	-446	-403	-373
Capital Expenditures (CapEx)	0.22	1.69	1.04	0.29	0.01	0.18	0.01	0.00	0.43	0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-32	-42	-49	-45	-30	-27	-20	-25	-20	-25
Debt-free Net Working Capital (DFNWC)	520	475	422	447	436	422	364	420	272	268
Net Working Capital (NWC)	520	475	422	447	436	422	364	420	272	268
Net Nonoperating Expense (NNE)	25	35	31	23	18	26	16	16	16	18
Net Nonoperating Obligations (NNO)	-651	-594	-525	-554	-503	-452	-400	-446	-403	-373
Total Depreciation and Amortization (D&A)	3.86	3.07	3.51	3.64	3.57	3.48	3.56	3.64	3.21	3.23
Debt-free, Cash-free Net Working Capital to Revenue	-42.27%	-27,066.67%	-39,475.20%	-30,327.89%	-17,566.27%	-28,064.21%	-23,436.78%	-38,167.69%	-45,860.47%	-111,877.27%
Debt-free Net Working Capital to Revenue	686.22%	304,548.72%	337,504.00%	304,340.14%	257,880.47%	444,248.42%	418,931.03%	645,875.38%	632,195.35%	1,217,559.09%
Net Working Capital to Revenue	686.22%	304,548.72%	337,504.00%	304,340.14%	257,880.47%	444,248.42%	418,931.03%	645,875.38%	632,195.35%	1,217,559.09%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.58)	($0.72)	($0.68)	($0.53)	($0.37)	($0.49)	($0.38)	($0.35)	($0.32)	($0.27)
Adjusted Weighted Average Basic Shares Outstanding	143.66M	143.15M	144.56M	146.80M	167.65M	156.93M	169.13M	190.03M	209.19M	194.81M
Adjusted Diluted Earnings per Share	($0.58)	($0.72)	($0.68)	($0.53)	($0.37)	($0.49)	($0.38)	($0.35)	($0.32)	($0.27)
Adjusted Weighted Average Diluted Shares Outstanding	143.66M	143.15M	144.56M	146.80M	167.65M	156.93M	169.13M	190.03M	209.19M	194.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	144.21M	144.50M	145.84M	167.63M	168.28M	169.09M	170.85M	209.11M	209.67M	217.26M
Normalized Net Operating Profit after Tax (NOPAT)	-58	-68	-69	-56	-44	-60	-49	-47	-43	-42
Normalized NOPAT Margin	0.00%	-71,076.53%	-231,214.67%	-256,263.64%	-200,441.82%	-283,696.67%	-221,149.09%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	-108,030.53%	-333,226.67%	-360,145.45%	-283,122.73%	-408,466.67%	-295,454.55%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-728.98	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-502.42	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-733.27	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-506.71	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Allogene Therapeutics' Financials

When does Allogene Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Allogene Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Allogene Therapeutics' net income changed over the last 2 years?

Allogene Therapeutics' net income appears to be on a downward trend, with a most recent value of -$257.59 million in 2024, falling from -$340.41 million in 2022. The previous period was -$327.27 million in 2023.

What is Allogene Therapeutics's operating income?

Allogene Therapeutics's total operating income in 2024 was -$273.20 million, based on the following breakdown:

Total Gross Profit: $22 thousand
Total Operating Expenses: $273.22 million

How has Allogene Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Allogene Therapeutics' total revenue changed from $156 thousand in 2022 to $22 thousand in 2024, a change of -85.9%.

How much debt does Allogene Therapeutics have?

Allogene Therapeutics' total liabilities were at $126.53 million at the end of 2024, a 3.1% decrease from 2023, and a 18.2% decrease since 2022.

How much cash does Allogene Therapeutics have?

In the past 2 years, Allogene Therapeutics' cash and equivalents has ranged from $61.90 million in 2022 to $83.16 million in 2023, and is currently $75.22 million as of their latest financial filing in 2024.

How has Allogene Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Allogene Therapeutics' book value per share changed from 4.62 in 2022 to 2.01 in 2024, a change of -56.5%.

Remove Ads

Related Companies

This page (NASDAQ:ALLO) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allogene Therapeutics (ALLO) Financials

Frequently Asked Questions About Allogene Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allogene Therapeutics (ALLO) Financials

Annual Income Statements for Allogene Therapeutics

Quarterly Income Statements for Allogene Therapeutics

Annual Cash Flow Statements for Allogene Therapeutics

Quarterly Cash Flow Statements for Allogene Therapeutics

Annual Balance Sheets for Allogene Therapeutics

Quarterly Balance Sheets for Allogene Therapeutics

Annual Metrics and Ratios for Allogene Therapeutics

Quarterly Metrics and Ratios for Allogene Therapeutics

Frequently Asked Questions About Allogene Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools